Anzeige
Mehr »
Sonntag, 08.06.2025 - Börsentäglich über 12.000 News
5-Dollar-Kupfer. KI-Infrastruktur. Energiewende. Vizsla Copper hat die Pfunde im Boden, die jetzt zählen.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWUQ | ISIN: US28658R1068 | Ticker-Symbol:
NASDAQ
06.06.25 | 21:56
1,395 US-Dollar
+12,50 % +0,155
1-Jahres-Chart
CLIMB BIO INC Chart 1 Jahr
5-Tage-Chart
CLIMB BIO INC 5-Tage-Chart

Aktuelle News zur CLIMB BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrOppenheimer initiates coverage on Climb Bio stock with outperform rating1
FrOppenheimer beginnt Berichterstattung über Climb Bio-Aktie mit Outperform-Rating 1
CLIMB BIO Aktie jetzt für 0€ handeln
DoClimb Bio, Inc. - 8-K, Current Report1
MiClym: ARD Money Maker portraitiert Solarpunk-Macher Clym1
22.05.BTIG sets Climb Bio stock Buy rating, $7 target2
19.05.Climb Bio, Inc.: Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)91WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases,...
► Artikel lesen
14.05.Climb Bio GAAP EPS of -$0.311
14.05.Climb Bio, Inc. - 10-Q, Quarterly Report-
14.05.Climb Bio, Inc. - 8-K, Current Report1
01.04.Climb Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans2
25.03.Climb Bio, Inc. - 8-K, Current Report1
25.03.Climb Bio, Inc.: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates556Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus...
► Artikel lesen
25.03.Climb Bio, Inc. - 10-K, Annual Report2
24.02.Climb Bio, Inc.: Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer356WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished...
► Artikel lesen
10.01.Climb Bio enters licensing deal with Mabworks for CLYM116 development1
10.01.Climb Bio, Inc. - 8-K, Current Report-
09.01.Climb Bio, Inc.: Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy227Transaction Expands Climb Bio's Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically...
► Artikel lesen
19.12.24Climb Bio, Inc.: Climb Bio to be Added to the Nasdaq Biotechnology Index134WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 - Climb Bio, Inc. (Nasdaq: CLYM) today announced that the company will be added to the NASDAQ Biotech Index (Nasdaq: NBI)...
► Artikel lesen
24.10.24Woodforest Acceptance Solutions Partners With Clym to Enhance Website Accessibility and Compliance With Consumer Privacy Regulations314Woodforest Acceptance Solutions Partners with Clym to Enhance Merchants' Compliance and Website Accessibility, Empowering Businesses to Navigate Digital Regulations Seamlessly THE WOODLANDS, TX / ACCESSWIRE...
► Artikel lesen
02.10.24Eliem Therapeutics, Inc.: Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.187Name change to "Climb Bio" marks the Company's transition and focus on developing treatments for immune-mediated diseases Climb Bio will begin trading on Nasdaq under the trading symbol "CLYM" effective...
► Artikel lesen
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1